Zurück zur Übersicht
| Cancers. 2022 Mar 20. pii: cancers14061579. doi: 10.3390/cancers14061579 |
| MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. |
| Heugenhauser J1, Galijasevic M2, Mangesius S3, Goebel G4, Buchroithner J5, Erhart F6, Pichler J7, Widhalm G8, Stockhammer G9, Iglseder S10, Freyschlag CF11, Oberndorfer S12, Bordihn K13, von Campe G14, Czech T15, Surböck B16, Urbanic Purkart T17, Marosi C18, Felzmann T19, Nowosielski M20 |
 Author information
|
|
Abstract INTRODUCTION: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). METHODS: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, = 40) or SOC + Audencel vaccine ( = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. RESULTS: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. CONCLUSION: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel. |
|
KEYWORDS: glioblastoma, iRANO, immunotherapy, mRANO, radiologic response criteria, volumetric measurements |
|
Publikations ID: 35326730 Quelle: öffnen |
Author information
Schnellinfo
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
